ClinicalTrials.gg
CompletedNCT01172938PALACE-1Updated Jun 19, 2020Results posted

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

A Phase 3 interventional study of Apremilast 20mg and Apremilast 30mg in Psoriatic Arthritis, sponsored by Amgen. Completed at 92 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-19.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
3rd of 17
504 · median 219
Started
2010
with 3 others
Phase 3
8 of 17
1 open now
Registered
2nd of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 2nd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Read the detailed description

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, reflects a complex interaction among resident dendritic, fibroblastic and endothelial cells, and inflammatory cells attracted to the synovium by cytokines and chemokines. Apremilast (CC-10004) is a novel oral agent that modulates multiple inflammatory pathways through targeted phosphodiesterase type 4 (PDE4) enzyme inhibition. Therefore, apremilast has the potential to be effective in the treatment of PsA.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Psoriatic Arthritis
  • Psoriasis
  • Arthritis
  • inflammation
  • skin condition
  • inflammatory cells
  • apremilast
  • CC-10004
  • phosphodiesterase type 4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, aged ≥ 18 years at time of consent.
  • Have a diagnosis of Psoriatic Arthritis (PSA, by any criteria) of ≥ 6 months duration.
  • Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at time of screening.
  • Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)
  • May not have axial involvement alone
  • Concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine
  • Have ≥ 3 swollen AND ≥ 3 tender joints.
  • Males \& Females must use
  • Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose oral allowed.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding.
  • History of allergy to any component of the product.
  • surface antigen and/or antibody positive at screening.
  • Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF) blocker
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    Apremilast 20 mg

    20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase

    Drug: Apremilast 20mg

  • Experimental
    Apremilast 30mg

    30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily

    Drug: Apremilast 30mg

  • Placebo comparator
    Placebo + 20 mg Apremilast

    Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16

    Drug: Placebo + 20 mg Apremilast

  • Placebo comparator
    Placebo + 30 mg Apremilast

    Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

    Drug: Placebo + 30 mg Apremilast

Interventions

  • Apremilast 20 mg twice daily, orally

    Also known as: CC-10004

  • Apremilast 30 mg twice daily, orally

    Also known as: CC-10004

  • DrugPlacebo + 20 mg Apremilast

    Placebo + 20 mg Apremilast

    Also known as: Placebo, CC-10004

  • DrugPlacebo + 30 mg Apremilast

    Placebo + 30 mg Apremilast

    Also known as: Placebo, CC-10004

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 16

  2. Percentage of Participants With an ACR 20 Response at Week 24

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response at Week 24. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 24

  4. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  5. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from Baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from Baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 16

  6. Change From Baseline in Patient's Assessment of Pain at Week 16

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 16

  7. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  8. Change From Baseline in Dactylitis Severity Score at Week 16

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  9. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 16

  10. Change From Baseline in the Disease Activity Score (DAS28) at Week 16

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 16

  11. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  12. Change From Baseline in SF-36 Physical Function at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  13. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: •78 tender joint count, •76 swollen joint count, •Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; •Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Patient's Assessment of Pain at Week 24

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 24

  15. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  16. Change From Baseline in Dactylitis Severity Score at Week 24

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  17. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

    Time frame: Baseline and Week 24

  18. Change From Baseline in the Disease Activity Score (DAS28) at Week 24

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 24

  19. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  20. Percentage of Participants With MASES Improvement ≥ 20% at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  21. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  22. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 16

  23. Percentage of Participants With MASES Improvement ≥ 20% at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  24. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  25. Percentage of Participants With Good or Moderate EULAR Response at Week 24

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 24

  26. Percentage of Participants With a ACR 50 Response at Week 16

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 16

  27. Percentage of Participants With an ACR 70 Response at Week 16

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 16

  28. Percentage of Participants With an ACR 50 Response at Week 24

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 24

  29. Percentage of Participants With a ACR 70 Response at Week 24

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and week 24

  30. Percentage of Participants Achieving a MASES Score of Zero at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Week 16

  31. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Week 16

  32. Percentage of Participants Achieving a MASES Score of Zero at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Week 24

  33. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Week 24

  34. Percentage of Participants With a ACR 20 Response at Week 52

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

    Time frame: Baseline and Week 52

  35. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 52

  36. Change From Baseline in the SF-36 Physical Functioning Domain at Week 52

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  37. Percentage of Participants With a Modified PsARC Response at Week 52

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from Baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from Baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  38. Change From Baseline in the Patient Assessment of Pain at Week 52

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 52

  39. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and week 52

  40. Change From Baseline in the Dactylitis Severity Score at Week 52

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 52

  41. Change From Baseline in the CDAI Score at Week 52

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 52

  42. Change From Baseline in the DAS28 at Week 52

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 52

  43. Change From Baseline in the FACIT-Fatigue Scale Score at Week 52

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  44. Percentage of Participants With MASES Improvement ≥ 20% at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  45. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  46. Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 52

  47. Percentage of Participants With an ACR 50 Response at Week 52

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  48. Percentage of Participants With an ACR 70 Response at Week 52

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  49. Percentage of Participants Achieving a MASES Score of Zero at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Week 52

  50. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Week 52

  51. Number of Participants With Adverse Events During the Placebo-Controlled Period

    A Treatment Emergent Adverse Event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Week 0 to Week 16 for placebo participants who entered early escape at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)

  52. Number of Participants With Adverse Events During the Apremilast-Exposure Period

    A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Baseline to Week 260; median total exposure to Apremilast was 170 weeks

07

Results

Posted May 20, 2014

Participant flow

This study was a multicenter study with 83 study sites from the US, Canada, Europe, Russia, Australia, New Zealand and South Africa.

Placebo-controlled Phase (Week 0-24)
Participant flow — Placebo-controlled Phase (Week 0-24)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Extension)Placebo/Apremilast 30 mg (Long-Term Extension)
Started168168168000000
Received treatment168168168000000
Completed week 16158158154000000
Early escape at week 161077858000000
Completed150146148000000
Not completed182220000000
Withdrew: Adverse event11810000000
Withdrew: Lack of efficacy454000000
Withdrew: Non-compliance with study drug012000000
Withdrew: Withdrawal by subject253000000
Withdrew: Death010000000
Withdrew: Protocol violation100000000
Withdrew: Other021000000
Active Treatment Phase (Weeks 25-52)
Participant flow — Active Treatment Phase (Weeks 25-52)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Extension)Placebo/Apremilast 30 mg (Long-Term Extension)
Started01361455123492400
Completed01241304419342200
Not completed012157415200
Withdrew: Adverse event025112000
Withdrew: Lack of efficacy047313000
Withdrew: Non-compliance with study drug001000000
Withdrew: Withdrawal by subject051229100
Withdrew: Lost to follow-up011100000
Withdrew: Other000001100
Active-Treatment Phase (Weeks 52-104)
Participant flow — Active-Treatment Phase (Weeks 52-104)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Extension)Placebo/Apremilast 30 mg (Long-Term Extension)
Started011812100006149
Completed09510000004645
Not completed023210000154
Withdrew: Adverse event021000031
Withdrew: Lack of efficacy078000040
Withdrew: Non-compliance with study drug002000000
Withdrew: Withdrawal by subject0108000052
Withdrew: Death001000000
Withdrew: Lost to follow-up011000030
Withdrew: Miscellaneous020000001
Withdrew: Missing010000000
Active-Treatment Phase Weeks (104-156)
Participant flow — Active-Treatment Phase Weeks (104-156)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Extension)Placebo/Apremilast 30 mg (Long-Term Extension)
Started09510000004645
Completed0849300004141
Not completed0117000054
Withdrew: Adverse event000000001
Withdrew: Lack of efficacy042000022
Withdrew: Withdrawal by subject063000021
Withdrew: Death000000010
Withdrew: Lost to follow-up010000000
Withdrew: Miscellaneious002000000
Active-Treatment Phase (Weeks 156-208)
Participant flow — Active-Treatment Phase (Weeks 156-208)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Extension)Placebo/Apremilast 30 mg (Long-Term Extension)
Started0849300004141
Completed0758800003234
Not completed095000097
Withdrew: Adverse event041000030
Withdrew: Lack of efficacy011000032
Withdrew: Withdrawal by subject042000024
Withdrew: Lost to follow-up001000001
Withdrew: Miscellaneous000000010
Active-Treatment Phase (Weeks 208-260)
Participant flow — Active-Treatment Phase (Weeks 208-260)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Extension)Placebo/Apremilast 30 mg (Long-Term Extension)
Started0758800003234
Switched from 20 mg to 30 mg bid0000000250
Completed0728000002932
Not completed038000032
Withdrew: Adverse event001000011
Withdrew: Lack of efficacy002000000
Withdrew: Non-compliance with study drug010000010
Withdrew: Withdrawal by subject023000010
Withdrew: Death001000000
Withdrew: Lost to follow-up001000000
Withdrew: Protocol violation000000001

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1619.030.438.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0001 · Adjusted difference: 19.0 · 95% CI 9.7 to 28.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% confidence interval (CI) is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0166 · Adjusted difference: 11.3 · 95% CI 2.2 to 20.4Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16-0.086 ± 0.0360-0.198 ± 0.0364-0.244 ± 0.0364
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0017 · Ls mean difference: -0.159 · 95% CI -0.258 to -0.060Based on an ANCOVA model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0252 · Ls mean difference: -0.113 · 95% CI -0.211 to -0.014Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With an ACR 20 Response at Week 24

Percentage of participants with an American College of Rheumatology 20% (ACR20) response at Week 24. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 20 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 20 Response at Week 2413.125.635.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 22.2 · 95% CI 13.4 to 30.9Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0038 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 12.4 · 95% CI 4.2 to 20.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24-0.076 ± 0.0369-0.211 ± 0.0373-0.258 ± 0.0371
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0005 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Ls mean difference: -0.182 · 95% CI -0.283 to -0.080Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0091 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Ls mean difference: -0.135 · 95% CI -0.236 to -0.034Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 161.81 ± 0.6213.50 ± 0.6254.23 ± 0.625
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0056 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Ls mean difference: 2.42 · 95% CI 0.71 to 4.13Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0504 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Ls mean difference: 1.70 · 95% CI -0.00 to 3.40Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from Baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from Baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 1629.838.746.4
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0017 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 16.7 · 95% CI 6.6 to 26.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 8.9 · 95% CI -1.2 to 18.9Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 16

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 16
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 16-5.7 ± 1.83-11.5 ± 1.85-13.5 ± 1.85
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0023 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Ls mean difference: -7.9 · 95% CI -12.9 to -2.8Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -5.8 · 95% CI -10.8 to -0.7Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16-0.9 ± 0.30-1.4 ± 0.29-1.3 ± 0.28
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.4 · 95% CI -1.2 to 0.4Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.5 · 95% CI -1.3 to 0.3Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 16

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 16-1.4 ± 0.28-1.9 ± 0.31-1.7 ± 0.28
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.3 · 95% CI -1.1 to 0.4Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.5 · 95% CI -1.3 to 0.3Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16-3.84 ± 0.929-8.24 ± 0.926-8.72 ± 0.923
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -4.88 · 95% CI -7.41 to -2.34Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -4.39 · 95% CI -6.92 to -1.86Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 16

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) at Week 16-0.26 ± 0.082-0.73 ± 0.082-0.79 ± 0.083
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.53 · 95% CI -0.76 to -0.31Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.47 · 95% CI -0.70 to -0.25Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 161.55 ± 0.6931.68 ± 0.6963.88 ± 0.695
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: 2.33 · 95% CI 0.43 to 4.23Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: 0.13 · 95% CI -1.77 to 2.03Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in SF-36 Physical Function at Week 24

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in SF-36 Physical Function at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in SF-36 Physical Function at Week 241.45 ± 0.6713.49 ± 0.6755.01 ± 0.671
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: 3.56 · 95% CI 1.72 to 5.40Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: 2.04 · 95% CI 0.21 to 3.88Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: •78 tender joint count, •76 swollen joint count, •Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; •Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 2418.531.042.9
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 24.6 · 95% CI 15.2 to 34.0Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 12.4 · 95% CI 3.4 to 21.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 24

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 24
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 24-4.2 ± 1.78-11.2 ± 1.79-14.7 ± 1.77
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: -10.6 · 95% CI -15.4 to -5.7Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -7.1 · 95% CI -12.0 to -2.2Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24-0.8 ± 0.31-1.6 ± 0.30-1.6 ± 0.29
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.8 · 95% CI -1.6 to 0.0Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.8 · 95% CI -1.6 to 0.1Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 24

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 24-1.3 ± 0.27-2.0 ± 0.30-1.8 ± 0.27
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.5 · 95% CI -1.2 to 0.3Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.7 · 95% CI -1.5 to 0.1Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24-3.14 ± 0.965-7.55 ± 0.958-9.52 ± 0.949
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -6.38 · 95% CI -9.00 to -3.75Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -4.41 · 95% CI -7.03 to -1.79Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 24

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) at Week 24-0.20 ± 0.087-0.66 ± 0.087-0.90 ± 0.087
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.70 · 95% CI -0.94 to -0.46Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.46 · 95% CI -0.70 to -0.22Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 241.12 ± 0.6911.52 ± 0.6963.33 ± 0.690
Statistical analysis
  • Placebo vs Apremilast 30 mg · Ls mean difference: 2.21 · 95% CI 0.32 to 4.10Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · Ls mean difference: 0.40 · 95% CI -1.50 to 2.29Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 1649.056.352.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 3.3 · 95% CI -10.1 to 16.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 7.3 · 95% CI -6.5 to 21.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 1657.466.160.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 2.9 · 95% CI -13.4 to 19.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 7.7 · 95% CI -9.1 to 24.6Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 1629.846.448.8
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 19.2 · 95% CI 9.0 to 29.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 16.6 · 95% CI 6.4 to 26.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 2446.958.360.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 13.2 · 95% CI -0.1 to 26.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 11.3 · 95% CI -2.4 to 25.0Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 2460.369.569.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 8.9 · 95% CI -6.8 to 24.6Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 7.7 · 95% CI -8.7 to 24.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Good or Moderate EULAR Response at Week 24

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate EULAR Response at Week 2416.130.442.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 26.3 · 95% CI 17.1 to 35.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 14.2 · 95% CI 5.4 to 23.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 50 Response at Week 16

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 50 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 50 Response at Week 166.015.516.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 10.3 · 95% CI 3.7 to 16.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 9.5 · 95% CI 3.0 to 16.0Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 70 Response at Week 16

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 161.26.04.2
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 3.1 · 95% CI -0.4 to 6.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 4.8 · 95% CI 0.8 to 8.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 50 Response at Week 24

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 244.214.319.0
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 14.9 · 95% CI 8.3 to 21.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 10.1 · 95% CI 4.0 to 16.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 70 Response at Week 24

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 70 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 70 Response at Week 240.65.410.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 9.5 · 95% CI 4.8 to 14.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 4.7 · 95% CI 1.2 to 8.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 1615.327.222.8
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 7.6 · 95% CI -2.8 to 17.9Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 11.9 · 95% CI 0.8 to 23.0Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 1639.742.438.2
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: -1.4 · 95% CI -17.7 to 14.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 2.4 · 95% CI -14.8 to 19.6Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 2414.331.131.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 17.4 · 95% CI 6.6 to 28.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 16.8 · 95% CI 5.6 to 27.9Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 2439.749.245.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Adjusted difference: 5.8 · 95% CI -10.7 to 22.4Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Adjusted difference: 8.8 · 95% CI -8.5 to 26.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 20 Response at Week 52

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 20 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 20 Response at Week 5253.1 (40.2 to 65.7)50.0 (36.8 to 63.2)63.0 (53.7 to 71.7)54.6 (45.7 to 63.4)
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52-0.27 ± 0.562-0.29 ± 0.590-0.37 ± 0.479-0.32 ± 0.547
SecondaryChange From Baseline in the SF-36 Physical Functioning Domain at Week 52

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the SF-36 Physical Functioning Domain at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the SF-36 Physical Functioning Domain at Week 524.46 ± 8.8774.62 ± 9.9796.98 ± 9.4255.69 ± 8.995
SecondaryPercentage of Participants With a Modified PsARC Response at Week 52

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from Baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from Baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified PsARC Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified PsARC Response at Week 5273.8 (60.9 to 84.2)71.2 (57.9 to 82.2)77.5 (69.0 to 84.6)73.6 (65.2 to 81.0)
SecondaryChange From Baseline in the Patient Assessment of Pain at Week 52

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 52
Reported as:
Mean · mm
Change From Baseline in the Patient Assessment of Pain at Week 52
mmPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Patient Assessment of Pain at Week 52-20.2 ± 26.76-21.0 ± 25.83-17.8 ± 24.50-20.3 ± 23.37
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and week 52
Reported as:
Mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52-2.2 ± 4.03-1.9 ± 3.89-2.7 ± 2.41-1.9 ± 2.93
SecondaryChange From Baseline in the Dactylitis Severity Score at Week 52

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Dactylitis Severity Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Dactylitis Severity Score at Week 52-0.8 ± 2.10-2.4 ± 3.58-2.7 ± 3.79-1.8 ± 3.23
SecondaryChange From Baseline in the CDAI Score at Week 52

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the CDAI Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the CDAI Score at Week 52-15.00 ± 11.137-14.03 ± 14.900-15.41 ± 13.039-14.54 ± 12.009
SecondaryChange From Baseline in the DAS28 at Week 52

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the DAS28 at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the DAS28 at Week 52-1.47 ± 1.103-1.15 ± 1.272-1.40 ± 1.125-1.31 ± 1.114
SecondaryChange From Baseline in the FACIT-Fatigue Scale Score at Week 52

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the FACIT-Fatigue Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the FACIT-Fatigue Scale Score at Week 524.33 ± 8.1834.15 ± 11.7124.27 ± 8.4883.67 ± 9.078
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 5269.4 (51.9 to 83.7)55.6 (38.1 to 72.1)84.1 (73.3 to 91.8)75.3 (65.0 to 83.8)
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 5265.2 (42.7 to 83.6)73.1 (52.2 to 88.4)85.4 (72.2 to 93.9)77.6 (63.4 to 88.2)
SecondaryPercentage of Participants Achieving Good or Moderate EULAR Response at Week 52

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 5282.870.075.074.4
SecondaryPercentage of Participants With an ACR 50 Response at Week 52

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 5225.4 (15.3 to 37.9)27.9 (17.1 to 40.8)24.8 (17.3 to 33.6)24.6 (17.5 to 32.9)
SecondaryPercentage of Participants With an ACR 70 Response at Week 52

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 524.8 (1.0 to 13.5)14.8 (7.0 to 26.2)15.4 (9.4 to 23.2)13.8 (8.4 to 21.0)
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 5233.3 (18.6 to 51.0)27.8 (14.2 to 45.2)50.7 (38.4 to 63.0)38.2 (28.1 to 49.1)
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 5252.2 (30.6 to 73.2)53.8 (33.4 to 73.4)68.8 (53.7 to 81.3)63.3 (48.3 to 76.6)
SecondaryNumber of Participants With Adverse Events During the Placebo-Controlled Period

A Treatment Emergent Adverse Event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Week 0 to Week 16 for placebo participants who entered early escape at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)
Reported as:
Number · participants
Number of Participants With Adverse Events During the Placebo-Controlled Period
participantsPlaceboApremilast 20 mgApremilast 30 mg
Treatment Emergent Adverse Events81101103
Drug-related TEAE325470
Severe TEAE6811
Serious TEAE (SAE)789
Drug-related Serious AE)203
TEAE leading to drug interruption91017
TEAE leading to drug withdrawal81012
TEAE leading to drug death010
SecondaryNumber of Participants With Adverse Events During the Apremilast-Exposure Period

A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Baseline to Week 260; median total exposure to Apremilast was 170 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events During the Apremilast-Exposure Period
participantsApremilast 20 mg (Pre-switch)Apremilast 20 mg/30 mg BID (Post-switch)Apremilast 30 mg BID
Treatment Emergent Adverse Events (TEAEs)20339131
Drug-related TEAE965131
Severe TEAE35130
Serious TEAE (SAE)41649
Drug-related SAE419
TEAE leading to drug interruption47349
TEAE leading to drug withdrawal27030
TEAE leading to death102

Adverse events

Collected over AE's are reported for the placebo-controlled phase and up to 5 years for all subjects randomized or re-randomized to apremilast at any time during the study. AEs were monitored and collected for 6 years, 4 months, 25 days excluding the end date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Week 0-24: Placebo (Placebo-Controlled Phase)—7/168 (4.2%)43/168 (25.6%)
Week 0-24: Apremilast 20 mg (Placebo- Controlled Phase)—8/168 (4.8%)69/168 (41.1%)
Week 0-24: Apremilast 30 mg (Placebo- Controlled Phase)—9/168 (5.4%)80/168 (47.6%)
Active Exposure up to 5 Years: Apremilast 20 mg—41/245 (16.7%)150/245 (61.2%)
Active Exposure Up to 5 Years: Apremilast 20/30 mg BID—6/87 (6.9%)17/87 (19.5%)
Active Exposure up to 5 Years: Apremilast 30 mg BID—49/245 (20%)169/245 (69%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventWeek 0-24: Placebo (Placebo-Controlled Phase)Week 0-24: Apremilast 20 mg (Placebo- Controlled Phase)Week 0-24: Apremilast 30 mg (Placebo- Controlled Phase)Active Exposure up to 5 Years: Apremilast 20 mgActive Exposure Up to 5 Years: Apremilast 20/30 mg BIDActive Exposure up to 5 Years: Apremilast 30 mg BID
PsoriasisSkin and subcutaneous tissue disorders0/1680/1680/1685/2450/870/245
OsteoarthritisMusculoskeletal and connective tissue disorders0/1680/1680/1682/2450/873/245
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/1680/1680/1680/2450/873/245
DepressionPsychiatric disorders0/1681/1680/1683/2450/870/245
Abdominal painGastrointestinal disorders0/1680/1680/1680/2451/871/245
IleusGastrointestinal disorders0/1680/1680/1681/2451/870/245
Cytomegalovirus infectionInfections and infestations0/1680/1680/1680/2451/870/245
Yersinia infectionInfections and infestations0/1680/1680/1680/2451/870/245
BursitisMusculoskeletal and connective tissue disorders0/1680/1680/1681/2451/870/245
Foot deformityMusculoskeletal and connective tissue disorders0/1680/1680/1680/2451/871/245
Most frequent other events
Showing 10 of 19
Most frequent other events
EventWeek 0-24: Placebo (Placebo-Controlled Phase)Week 0-24: Apremilast 20 mg (Placebo- Controlled Phase)Week 0-24: Apremilast 30 mg (Placebo- Controlled Phase)Active Exposure up to 5 Years: Apremilast 20 mgActive Exposure Up to 5 Years: Apremilast 20/30 mg BIDActive Exposure up to 5 Years: Apremilast 30 mg BID
DiarrhoeaGastrointestinal disorders4/16820/16832/16833/2451/8751/245
NauseaGastrointestinal disorders11/16816/16832/16830/2450/8741/245
Upper respiratory tract infectionInfections and infestations6/16810/1687/16841/2453/8736/245
HeadacheNervous system disorders8/16817/16818/16831/2452/8734/245
NasopharyngitisInfections and infestations5/1687/1688/16830/2453/8731/245
HypertensionVascular disorders2/1686/1682/16820/2454/8726/245
SinusitisInfections and infestations4/1684/1684/16821/2452/8721/245
Gastrooesophageal reflux diseaseGastrointestinal disorders1/1681/1685/16810/2451/8719/245
BronchitisInfections and infestations2/1682/1680/16817/2453/8719/245
DepressionPsychiatric disorders1/1684/1681/16817/2451/8710/245

Baseline characteristics

Full analysis set consisting of all participants who were randomized as specified in the protocol.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean51.1 ± 12.1348.7 ± 10.9951.4 ± 11.7250.4 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Female808392255
Male888576249
Duration of psoriatic arthritis
Duration of psoriatic arthritis(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean7.31 ± 7.1187.18 ± 6.8428.09 ± 8.0927.53 ± 7.366
08

Study locations

92 sites
  • Achieve Clinical Research LLC
    Birmingham, Alabama 35216, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • UCSD-Thornton Hospital
    La Jolla, California 92093-0943, United States
  • Stanford University Medical Center
    Palo Alto, California 94304-1808, United States
  • Inland Rheumatology Clinical Trials
    Upland, California 91786, United States
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • North Florida Dermatology
    Jacksonville, Florida 32204, United States
  • Tampa Medical Group Pa
    Tampa, Florida 33614, United States
  • Sonora Clinical Research, LLC
    Boise, Idaho 83702, United States
  • Coeur D'Alene Arthritis Clinic
    Coeur d'Alene, Idaho 83814, United States
  • The Arthritis Center
    Springfield, Illinois 62704, United States
  • St. Francis Hospital and Health Centers
    Michigan City, Indiana 46360, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Justus Fiechtner MD PC
    Lansing, Michigan 48910, United States
  • Physicians East
    Greenville, North Carolina 27834, United States
  • Carolina Bone and Joint
    Monroe, North Carolina 28112, United States
  • Piedmont Medical Research Associates Inc
    Winston-Salem, North Carolina 27103-3914, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading, LLP
    West Reading, Pennsylvania 19610, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Accurate Clinical Research Inc
    Houston, Texas 77034, United States
  • Arthritis and Osteoporosis Associates LLP
    Lubbock, Texas 79424, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98104, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Eastern Health Clinical School
    Box Hill, 3128, Australia
  • Repatriation General Hospital
    Daws Park, 5041, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, 3065, Australia
  • Emeritus Research
    Malvern, 3145, Australia
  • Ordination Wien Dr. Hanusch
    Vienna, 1060, Austria
  • Medizinische Universitat Wien
    Vienna, 1090, Austria
  • Kaiser-Franz-Josef Spital
    Wien, 1100, Austria
  • Nexus Clinical Research
    St John's, Newfoundland and Labrador A1A 5E8, Canada
  • St. Clare's Health Care Corporation of St. John's
    St John's, Newfoundland and Labrador A1C-5B8, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • MAC Research Incorporated
    Hamilton, Ontario L8N 2B6, Canada
  • K-W Musculoskeletal Research Inc.
    Kitchener, Ontario N2M 5N6, Canada
  • Saint Josephs Healthcare System
    London, Ontario N6A 4V2, Canada
  • Credit Valley Professional Building
    Mississauga, Ontario L5M 2V8, Canada
  • The Arthritis Program Research Group Inc.
    Newmarket, Ontario L3Y 3R7, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 258, Canada
  • Probity Medical Research Inc
    Waterloo, Ontario N2J 1C4, Canada
  • Jude Rodrigues Private Practice
    Windsor, Ontario N8X 5A6, Canada
  • Hospital Maisonneuve - Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Institut de Rhumatologie de Montreal
    Montreal, Quebec H2L 1S6, Canada
  • Centre de Rhumatologie St-Louis
    Sainte Foy, Quebec G1W 4R4, Canada
  • Centre Hospitalier Universitaire de Sherbrooke-Hospital Fleurimont
    Sherbrooke, Quebec J1H5N4, Canada
  • Saskatoon Osteoporosis Centre
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Ipros - Chr Orleans
    Orleans, 45067, France
  • Hopital Purpan
    Toulouse Cedex, 31009, France
  • Klinikum Duisburg, Wedau Kliniken
    Duisburg, 47055, Germany
  • Friedrich-Alexander-Universiät Erlangen Nürnberg
    Erlangen, 91054, Germany
  • Allgemeines Krankenhaus Eilbeck
    Hamburg, 22081, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, 44652, Germany
  • Praxis Prof. Herbert Kellner
    München, 80639, Germany
  • Qualiclinic kft
    Budapest, 1036, Hungary
  • Synexus Magyarország Kft.
    Budapest, 1036, Hungary
  • Honvéd Kórház - Állami Egészségügyi Központ
    Budapest, 1062, Hungary
  • MAV Korhaz es Rendelointezet Szolnok
    Szolnok, 5000, Hungary
  • Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet
    Veszprém, 8200, Hungary
  • P3 Research
    Crofton Downs, 6035, New Zealand
  • Waikato hospital
    Hamilton, 3204, New Zealand
  • Middlemore Clinical Trials
    New Zealand, 1640, New Zealand
  • Queen Elizabeth Hospital for Rheumatic Disease
    Rotorua, 3201, New Zealand
  • North Shore Hospital
    Takapuna, 1309, New Zealand
  • Timaru Hospital
    Timaru, 8601, New Zealand
  • Szpital Uniwersytecki im. Dr A.Jurasza
    Bydgoszcz, 85-096, Poland
  • Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Synexus SCM Sp. z o.o.
    Gdynia, 81-384, Poland
  • Synexus SCM Sp. z o.o.
    Katowice, Poland, Poland
  • Wojewodzki Zespol Reumatologiczny
    Sopot, 81-759, Poland
  • Synexus SCM Sp. z o.o. Oddz. Warszawa
    Warszawa, 01-192, Poland
  • Kemerovo State Medical Academy
    Kemerovo, 650066, Russian Federation
  • Ryazan I.P. Pavlov State Medical University
    Ryazan, 390026, Russian Federation
  • Departmental Hospital at Smolensk Station RZhD JSC
    Smolensk, 214025, Russian Federation
  • Regional Clinical Hospital
    Vladimir, 600023, Russian Federation
  • Voronezh Regional Clinical Hopsital #1, Voronezh State Medical Academy
    Voronezh, 394066, Russian Federation
  • Panorama Medical Centre
    Cape Town, 7500, South Africa
  • Groote Schuur Hospital
    Cape Town, 7925, South Africa
  • Chelmsford Medical Centre 2
    Durban, 4001, South Africa
  • Clinresco Centres Pty Ltd
    Johannesburg, 1619, South Africa
  • The Park
    Pinelands, 7700, South Africa
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, 15706, Spain
  • Barnsley Hospital
    Barnsley South Yorkshire, S75 2EP, United Kingdom
  • Colchester General Hospital
    Colchester, CO4 5JL, United Kingdom
  • West Suffolk Hospital
    Edmunds, IP33 2QZ, United Kingdom
09

References and documents

Publications

  • Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015 Mar;42(3):479-88. doi: 10.3899/jrheum.140647. Epub 2015 Jan 15. PubMed 25593233 ↗
  • Mease PJ, Gladman DD, Kavanaugh A, McGonagle D, Nash P, Guerette B, Nakasato P, Brunori M, Teng L, McInnes IB. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatol Ther. 2021 Dec;8(4):1677-1691. doi: 10.1007/s40744-021-00369-x. Epub 2021 Sep 18. PubMed 34536218 ↗
  • Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A, McInnes I, Queiro R, Guerette B, Brunori M, Teng L, Smolen JS. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care Res (Hoboken). 2020 Jun;72(6):814-821. doi: 10.1002/acr.24134. Epub 2020 May 8. PubMed 31909868 ↗
  • Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3. PubMed 31077258 ↗
  • Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018. PubMed 30018799 ↗
  • Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4. PubMed 24595547 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Apr 2012, 22 months.

Results were first posted in May 2014, 2 years after primary completion. A results delay was requested in May 2013.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 22 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2010
First posted
Jul 30, 2010
StartActual
Jun 2, 2010
Primary completionActual
Apr 27, 2012
CompletionActual
Oct 27, 2016
Results delay requested
May 29, 2013
Results first posted
May 20, 2014
Last update
Jun 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01172938
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 30, 2010
Start date
Jun 2, 2010
Primary completion
Apr 27, 2012
Completion
Oct 27, 2016
Results posted
May 20, 2014
Last update
Jun 19, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion